Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07593196 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HER2-positive Metastatic Breast Cancer in Kazakhstan

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Sep 30, 2026 → Dec 31, 2026
See other at-risk trials from AstraZeneca

Record History

  1. Recruitment opened Primary completion pushed from Sep 30, 2026 to Dec 31, 2026 · Completion moved earlier from Jan 30, 2027 to Dec 31, 2026 · Start date changed from estimate of May 19, 2026 to Jun 12, 2026 · 2 more Show 5 more changesShow less
    • Primary completion pushed from Sep 30, 2026 to Dec 31, 2026
    • Completion moved earlier from Jan 30, 2027 to Dec 31, 2026
    • Start date changed from estimate of May 19, 2026 to Jun 12, 2026
    • Eligibility criteria expanded, about 7 words
    • Study sites revised (12)
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Planned study population consists of approximately 240 adult patients with HER2-positive mBC receiving anti-HER2 therapy in 12 oncological centers (in each center it is expected to recruit about 20 patients) in different regions in order to provide representative study sample. Patients will be included consecutively from the least recent diagnosis (within defined time period). Planned retrospective follow-up period for 1 patient is a period starting from the date of mBC diagnosis until end study or until patient's death, whichever occurs first. End of study will be at least 12 months after the latest date of mBC diagnosis to ensure all patients have the opportunity to contribute at least 12 months of data.
Trial Details
NCT Number NCT07593196
Lead Sponsor AstraZeneca
Conditions Metastatic Breast Cancer
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov